Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

NCT01035593 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT01035593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01035593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2010
Completion date
December 31, 2011
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft rejection, kidney transplantation